Zdybski Med Sp. z o.o.
- Address
- Ul. Henryka Sienkiewicza 65/14, 27-400 Lublin, Poland
Atopic Dermatitis and Other Immune-Mediated Skin Diseases
At Zdybski Med Sp. z o.o. in Lublin, a major share of the research focuses on immune system diseases and skin and connective tissue diseases, especially atopic dermatitis. The trials are designed to assess new treatment options, compare them with placebo, and understand how well they control symptoms over time.
- Testing new therapies for moderate to severe atopic dermatitis
- Evaluating long-term safety and durability of treatment response
- Comparing treatment effectiveness against placebo in patients with persistent disease
This area includes both adult and pediatric research, reflecting a broad effort to improve care for people living with chronic inflammatory skin conditions.
Vitiligo and Pigment-Related Disorders
The site also takes part in studies on vitiligo, with research aimed at improving repigmentation and expanding treatment choices for both adults and children. These trials are focused on determining whether newer therapies can help restore skin color more effectively than standard approaches or placebo.
- Studying treatment effectiveness in nonsegmental vitiligo
- Assessing options for pediatric vitiligo
- Exploring therapies intended to improve visible skin changes and quality of life
This research reflects a strong interest in conditions where visible symptoms can have a major impact on daily life and self-confidence.
Urticaria, Alopecia Areata, and Other Dermatologic Conditions
Additional trials at the Klinika Zdybski Lublin site address a wider range of dermatologic and immune-related disorders, including chronic spontaneous urticaria, alopecia areata, hidradenitis suppurativa, prurigo nodularis, and palmoplantar pustulosis. The goal is to evaluate whether emerging treatments can better reduce symptoms, support hair regrowth, and improve disease control.
- Investigating symptom relief in chronic spontaneous urticaria
- Studying hair regrowth treatments for alopecia areata
- Assessing new options for hidradenitis suppurativa, prurigo nodularis, and palmoplantar pustulosis
- Including a study on moderate to severe platysma prominence, showing interest in both medical and aesthetic dermatology
Overall, the research portfolio combines chronic inflammatory skin disease studies with broader dermatology-focused trials aimed at improving patient outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Incyte Corp.2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Incyte Corp.4trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Zdybski Med Sp. z o.o.
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3, randomized, double-blind, placebo-controlled, multicenter study with open-label extension to evaluate the efficacy and safety of bimekizumab in study participants with palmoplantar pustulosis | UCB Biopharma | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 3 | Unknown | 2022-11-10 | 2024-10-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.